Rosacea AIMN Cream (Azelaic Acid / Ivermectin / Metronidazole / Niacinamide) (30 mL)

Rosacea AIMN Cream is a specialized topical formulation created to help manage the symptoms of rosacea, such as facial redness, inflammation, and skin sensitivity. It is designed to provide gentle yet effective care for irritated skin, offering relief from discomfort while improving skin texture and appearance. The cream’s nourishing ingredients support the skin’s barrier function, helping it retain moisture and maintain resilience against environmental triggers. Regular application of Rosacea AIMN Cream helps calm flare-ups and promotes a more even, healthy-looking complexion.

Rosacea AIMN Cream works by targeting inflammation and strengthening the skin’s natural protective layers. The active ingredients help reduce redness and swelling by calming the blood vessels and soothing irritated tissue. The cream also helps enhance skin hydration, preventing dryness that can exacerbate rosacea symptoms. By supporting skin regeneration and reducing inflammation, it assists in minimizing discomfort such as burning or itching sensations. Over time, continuous use helps restore skin balance and reduce sensitivity to external factors like temperature changes and stress.

Rosacea AIMN Cream should be avoided by individuals who are allergic to any of its ingredients. It is not recommended for use on open wounds, severely cracked, or infected skin. Before applying the cream widely, it’s advisable to perform a patch test to ensure the product is suitable for your skin type. If irritation, rash, or excessive dryness occurs, stop using the cream immediately and consult a healthcare professional. Avoid applying it near the eyes, lips, or mucous membranes, and ensure it is kept out of reach of children. Use only as directed by a healthcare provider.

Most users tolerate Rosacea AIMN Cream well, but some may experience mild side effects during the initial stages of treatment. Common reactions include temporary redness, slight itching, stinging, or dry patches where the cream is applied. These effects often diminish as the skin adapts to the formulation. However, those with highly sensitive skin may experience more pronounced irritation or discomfort. If any side effects persist or become severe, discontinue use and seek medical advice. The cream is designed for gentle care, and in most cases, side effects are minimal and short-lived.

If you are pregnant or breastfeeding, consult your healthcare provider before using Rosacea AIMN Cream. While the cream is applied externally and generally considered safe, certain ingredients may be absorbed through the skin, and hormonal changes during pregnancy can make skin more reactive. A doctor can help determine if the cream is suitable for your specific condition and stage of pregnancy or breastfeeding. With proper medical guidance, the cream can be used safely as part of a skincare routine to help manage rosacea symptoms while protecting both mother and child.

Store this medication in its original container at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light. Keep all medicine out of the reach of children. Throw away any unused medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain.

1. Del Rosso, James Q. “Azelaic Acid Topical Formulations: Differentiation of 15% Gel and 15% Foam.” The Journal of Clinical and Aesthetic Dermatology 10.3 (2017): 37–40. Print.
2. Fariba Iraji, Ali Sadeghinia, Zabiholah Shahmoradi, Amir Hossein Siadat, Abolfazl Jooya. Efficacy of topical azelaic acid gel in the treatment of mild-moderate acne vulgaris. Department of Dermatology, Al-Zahra Hospital.
3. Cutis [01 Jan 1996, 57(1 Suppl):36-45]. Melanin hyperpigmentation of skin: melasma, topical treatment with azelaic acid, and other therapies.
4. Chouela E, Abeldano A, et el. Arch Dematol 1999;135:651-5.
5. del Giudice P, Chosidow O, Caumes E. Ivermectin in dermatology. J Drugs Dermatol 2003;2:13-21.
6. Richard-Lenoble D, Chandenier J, and Gaxotte P. Ivermectin and filariasis. Fundam Clin Pharmacology 2003;17:199-203.
7. Ottesen EA, Campbell WC. Ivermectin in human medicine. J Antimicrobial Chemotherapy 1994;34:195-203.
8. Lamp KC, Freeman CD, Klutman NE, et al. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 1999;36:353-373.
9. Duck WM, Sobel J, Pruckler JM, et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 2004;10:1088-1094.
10. Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: The surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 2002;136:13-24.
11. Chey WD, Leontiadis GI, Howden CW, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2017;112:212-238.
12. Flagyl (metronidazole tablets) package insert. New York, NY: Pfizer, Inc.; 2021 Mar.
13. Niaspan (niacin extended-release) tablet package insert. North Chicago, IL: Abbott Laboratories; 2015 Apr.
14. HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203-12.
15. Taylor AJ, Villines TC, Stanck EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009. Epub ahead of print, doi:10.1056/NEJMoa907569.
16. Lee JMS, Robson MD, Yu LM, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: A randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009;54:1787—94.
17. McKenney JM, et al. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672-7.
18. Finacea (azelaic acid) topical gel package insert. Whippany, NJ: Bayer Healthcare; 2016 Aug.
19. Finacea (azelaic acid) 15% topical foam package insert. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; 2015 Jul.
20. US Food and Drug Administration (FDA). FDA Medwatch: ivermectin intended for animals: letter to stakeholders – do not use in humans as a treatment for COVID-19. Retrieved April 14, 2020. Available on the World Wide Web at:https://www.fda.gov/safety/medical-product-safety-information/ivermectin-intended-animals-letter-stakeholders-do-not-use-humans-treatment-covid-19.– LinkOpens in New Tab
21. US Food and Drug Administration (FDA). FDA Medwatch consumer updates: why you should not use ivermectin to treat or prevent COVID-19. Retrieved March 8, 2021. Available on the World Wide Web at: https://www.fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectin-treat-or-prevent-covid-19.– LinkOpens in New Tab
22. Stromectol (ivermectin) package insert. Whitehouse Station, NJ: Merck and Co., Inc.; 2018 Feb.
23. Soolantra (ivermectin) package insert. Fort Worth, TX: Galderma Laboratories; 2018 Apr.
24. American Academy of Pediatrics (AAP) Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108(3):776-789.
25. Sklice (ivermectin lotion) package insert. Atlanta, GA: Arbor Pharmaceuticals; 2017 Jun.
26. Sklice OTC (ivermectin lotion) package insert. Atlanta, GA: Arbor Pharmaceuticals; 2020 Oct.
27. Metronidazole injection package insert. Deerfield, IL: Baxter Healthcare Corporation; 2021 Mar.
28. Roden, DM. Drug-induced prolongation of the QT interval. New Engl J Med 2004;350:1013-22.
29. Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug-related QT interval prolongation. Pharmacotherapy 2003;23:881-908.
30. van Noord C, Eijgelsheim M, Stricker BH. Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 2010;70(1):16-23.
31. Altin C, Kanyilmaz S, Baysal S, et al. QT interval prolongation due to metronidazole administration. Anadolu Kardiyol Derg 2011;11:46-9.
32. Cohen O, Saar N, Swartzon M, et al. First report of metronidazole-induced QT interval prolongation. Int J Antimicrob Agents 2008;31:180-81.
33. Woosley RL, Heise CW, Gallo T, et al. QTFactors List. Oro Valley, AZ: AZCERT, Inc.; Accessed March 31, 2020. Available on the World Wide Web at: https://crediblemeds.org/ndfa-list/– LinkOpens in New Tab
34. Flagyl ER (metronidazole extended release tablets) package insert. New York, NY: Pfizer, Inc.; 2021 Mar.
35. Flagyl (metronidazole capsules) package insert. New York, NY: Pfizer, Inc.; 2021 Mar.
36. Metrogel (metronidazole gel), 1% package insert. Fort Worth, TX: Galderma Laboratories, L.P.; 2011 Oct.
37. Metrogel (metronidazole gel 1%) package insert. Forth Worth, TX: G.D. Galderma Laboratories; 2011 Oct.
38. MetroCream (metronidazole 0.75% topical cream). Forth Worth, TX: Galderma Laboratories, L.P.; 2002 Dec.
39. Metrogel-Vaginal (metronidazole gel) package insert. Bristol, TN: Graceway Pharmaceuticals, LLC; 2007 Apr.
40. Centers for Disease Control and Prevention (CDC). Sexually Transmitted Diseases Treatment Guidelines 2015. MMWR. 2015;64(3):1-137
41. Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016). J Pediatr Gastroenterol Nutr 2017;64:991-1003.
42. Health Care Financing Administration. Interpretive Guidelines for Long-term Care Facilities. Title 42 CFR 483.25(l) F329: Unnecessary Drugs. Revised 2015.
43. Vandazole (metronidazole vaginal gel 0.75%) package insert. Maple Grove, MN: Upsher-Smith Laboratories, Inc.; 2021 Feb.
44. Muanda FT, Sheehy O, Berard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: A population based cohort study. Br J Clin Pharmacol 2017; July 19 [Epub ahead of print].
45. Muanda FT, Sheehy O, Berard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. CMAJ 2017;189:e625-e633.
46. Nuvessa (metronidazole vaginal gel 1.3%) package insert. Florham Park, NJ: Exeltis USA, Inc.; 2018 Aug.
47. Passmore CM, McElnay JC, Rainey EA et al. Metronidazole excretion in human milk and its effect on the suckling neonate. Br J Clin Pharmacol. 1988;26:45-51.
48. Erickson SH, Oppenheim GL, Smith GH. Metronidazole in breast milk. Obstet Gynecol 1981;57:48-50.
49. Heisterberg L, Branebjerg PE. Blood and milk concentrations of metronidazole in mother and infants. J Perinat Med 1983;11:114-20.
50. [No authors listed]. An evaluation of metronidazole in the prophylaxis of anaerobic infections in obstetrical patients. J Antimicrob Chemother 1978;4 Suppl C:55-62.
51. Vancocin HCl capsules (vancomycin hydrochloride) package insert. Baudette, MN: Ani Pharmaceuticals, Inc.; 2021 Jan.
52. Vancomycin 10 g bulk intravenous vials package insert. Lake Forest, IL: Hospira, Inc.; 2021 Mar.
53. Colletti RB, Neufeld EJ, Roff NK, et al. Niacin treatment of hypercholesterolemia in children. Pediatrics 1993;92:78-82.
54. Expert Panel: National Cholesterol Education Program. Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 1992;89(suppl 2):525-84.
55. Niacinamide. In: Drugs in Pregnancy and Lactation. A Reference Guide to Fetal and Neonatal Risk. Briggs GG, Freeman RK, Yaffe SJ, (eds.) 7th ed., Philadelphia PA: Lippincott Williams and Wilkins; 2005:1140-1
56. Azelex (azelaic acid) package insert. Irvine, CA: Allergan, Inc.; 2004 May.
57. Azelex (azelaic acid) package insert. Irvine, CA: Allergan, Inc.; 2004 May.
58. Azelex (azelaic acid cream) 20% [package insert]. Irvine, CA: Allergan; 2013.
59. Homeida MM, Bagi IA, Ghalib HW, et al. Prolongation of prothrombin time with ivermectin. Lancet 1988;1:1346-7.
60. Whitworth JA, Hay CR, McNicholas AM, et al. Coagulation abnormalities and ivermectin. Ann Trop Med Parasitol 1992;86:301-5.
61. Richards FO, McNeely MB, Bryan RT, et al. Ivermectin and prothrombin time. Lancet 1989;1:1139.
62. Pacque MC, Munoz B, White AT, et al. Ivermectin and prothrombin time. Lancet 1989;1:1140.
63. MetroLotion (metronidazole 0.75% topical lotion) package insert. Fort Worth, TX: Galderma Laboratories, L.P.; 2015 Oct.
64. Vitazol (metronidazole 0.75% topical cream) package insert. Rochester, NY: Rochester Pharmaceuticals; 2009 Dec.
65. Noritate (metronidazole 1% topical cream) package insert. Bridgewater, NJ: Dermik Laboratories; 2006 Dec.
66. Metronidazole (Metro IV) injection package insert. Bethlehem, PA: B.Braun Medical Inc.; 2021 Apr.
67. Niacor (Niacin tablets) package insert. Minneapolis, MN: Upsher-Smith Laboratories, Inc.; 2000 Feb.